- Secukinumab in the treatment of psoriasis2016 | Third Faculty of Medicine
- Bimekizumab - a new treatment option for axial spondyloarthritis2023 | First Faculty of Medicine
- Bimekizumab v léčbě psoriázy2022 | First Faculty of Medicine
- Secukinumab in treating psoriatic arthritis2017 | First Faculty of Medicine
- Expansion of T helper type 17 lymphocytes in patients with chronic granulomatous disease2011 | Second Faculty of Medicine
- Aging in psoriasis vulgaris: female patients are epigenetically older than healthy controls2021 | Faculty of Medicine in Hradec Králové
- Ustekinutab in the treatment of psoriasis2017 | Publication without faculty affiliation
- Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial2020 | Faculty of Medicine in Pilsen
- Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe2023 | First Faculty of Medicine
- Interleukin-17A Gene Variability in Patients with Type 1 Diabetes Mellitus and Chronic Periodontitis: Its Correlation with IL-17 Levels and the Occurrence of Periodontopathic Bacteria2016 | Publication without faculty affiliation
- Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors - brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry2022 | Third Faculty of Medicine, First Faculty of Medicine, Faculty of Medicine in Pilsen, Central Library of Charles University
- Dietary gluten alters the balance of pro-inflammatory and anti-inflammatory cytokines in T cells of BALB/c mice2013 | Third Faculty of Medicine
- Immunogenicity and safety of the booster BNT162b2 vaccine in patients with axial spondyloarthritis treated with biological disease-modifying drugs2022 | Second Faculty of Medicine
- ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update2023 | First Faculty of Medicine
- Real-world Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients with Psoriatic Arthritis in Thirteen European Countries2022 | First Faculty of Medicine
